Biogen
BIIB
996 hedge funds and large institutions have $35B invested in Biogen in 2023 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 341 increasing their positions, 363 reducing their positions, and 99 closing their positions.
11% more call options, than puts
Call options by funds: $748M | Put options by funds: $674M
11% more capital inflows, than outflows
Capital inflows: $2.8B | Capital outflows: $2.53B
0.33% more ownership
Funds ownership: 86.75% → 87.08% (+0.33%)
6% less repeat investments, than reductions
Existing positions increased: 341 | Existing positions reduced: 363
3% less funds holding
Funds holding: 1,030 → 996 (-34)
16% less first-time investments, than exits
New positions opened: 83 | Existing positions closed: 99
24% less funds holding in top 10
Funds holding in top 10: 25 → 19 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$509M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$191M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$150M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$110M |
| 5 |
Carmignac Gestion
Paris,
France
|
+$85.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$197M |
| 2 |
Man Group
London,
United Kingdom
|
-$192M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$147M |
| 4 |
Two Sigma Advisers
New York
|
-$139M |
| 5 |
D.E. Shaw & Co
New York
|
-$117M |
BIIB Hedge Fund Activity: Q1 2023 in Review
996 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2023, worth a combined $35B — up 1.3% from $34.6B a quarter earlier.
Sellers outnumbered buyers: 99 funds closed out of BIIB and 83 opened new positions — a net loss of 16 holders — while 363 trimmed existing stakes and 341 added.
The largest buyer was JP Morgan Chase, adding an estimated $509M. The largest seller was Marshall Wace, cutting an estimated $197M.
- 996 institutional investors held Biogen (BIIB) as of Q1 2023, down from 1,030 in Q4 2022.
- Funds reported $35B of Biogen stock for Q1 2023, up 1.3% quarter-over-quarter.
- 83 funds opened new Biogen positions in Q1 2023 and 99 closed out, a net change of -16 holders.
- The largest Biogen buyer in Q1 2023 was JP Morgan Chase, an estimated $509M added.
- The largest Biogen seller in Q1 2023 was Marshall Wace, an estimated $197M sold.
Based on aggregated 13F filings for Q1 2023.